ArticleBioinformatics (Oxford, England)2025
Debiased machine learning for ultra-high dimensional mediation analysis.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
motivationIn ultra-high dimensional mediation analysis, confounding variables can influence both mediators and outcomes through complex functional forms. While machine learning (ML) approaches are effective at modeling such complex relationships, they can introduce bias when estimating mediation effects. In this article, we propose a debiased ML framework that mitigates this bias, enabling accurate identification of key mediators and precise estimation and inference of their respective contributions.
resultsWe construct an orthogonalized score function and use cross-fitting to reduce bias introduced by ML. To tackle ultra-high dimensional potential mediators, we implement screening and regularization techniques for variable selection and effect estimation. For statistical inference of the mediators' contributions, we use an adjusted Sobel-type test. Simulation results demonstrate the superior performance of the proposed method in handling complex confounding. Applying this method to Alzheimer's Disease Neuroimaging Initiative data, we identify several cytosine-phosphate-guanine sites where DNA methylation mediates the effect of body mass index on Alzheimer's Disease. AVAILABILITY AND IMPLEMENTATION: The R function DML_HDMA implementing the proposed methods is available online at https://github.com/Wei-Kecheng/DML_HDMA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.